Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer
– Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality –– Data to be […]